Agios Pharma (AGIO) Stock Forecast & Price Target

Compare

674 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AGIO Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Agios

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AGIO Stock 12 Month Forecast

Average Price Target

$34.17

▲(25.30% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is $34.17 with a high forecast of $48.00 and a low forecast of $25.00. The average price target represents a 25.30% change from the last price of $27.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","59":"$59","32.75":"$32.8","41.5":"$41.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,32.75,41.5,50.25,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,29.39076923076923,30.94153846153846,32.49230769230769,34.043076923076924,35.59384615384615,37.144615384615385,38.69538461538461,40.246153846153845,41.79692307692308,43.347692307692306,44.89846153846153,46.449230769230766,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,28.326923076923077,28.813846153846153,29.30076923076923,29.787692307692307,30.274615384615384,30.761538461538464,31.24846153846154,31.735384615384618,32.222307692307695,32.70923076923077,33.19615384615385,33.683076923076925,{"y":34.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,27.62153846153846,27.403076923076924,27.184615384615384,26.966153846153848,26.747692307692308,26.529230769230768,26.310769230769232,26.092307692307692,25.873846153846152,25.655384615384616,25.436923076923076,25.21846153846154,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.00

Average Price Target$34.17

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Agios Pharma (NASDAQ: AGIO) and Phreesia (NYSE: PHR)

Alec Stranahan

Bank of America Securities

$32

Buy

17.35%

Upside

Reiterated

12/09/25

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)We reiterate Buy and $32 PO.

Tessa Romero

J.P. Morgan

―

Hold

―

Reiterated

12/08/25

Agios Pharma: Hold Rating Amid Regulatory Uncertainty and Gradual Market Launch

Emily Bodnar

H.C. Wainwright

$48

Buy

76.02%

Upside

Reiterated

12/08/25

Anticipated FDA Approval of Agios Pharma's Pyrukynd Expected to Boost Stock ValueValuation and Risks. Our Buy rating and $48 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2038 and assign a 10% discount rate and -25% terminal growth rate. We are currently modeling mitapivat with 100% POS in PKD, 90% POS in thalassemia, and 50% POS in SCD, and have not included other pipeline assets or indications in our valuation.

Samantha Semenkow

Citi

$38

Buy

39.35%

Upside

Initiated

11/26/25

Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)

Andrew Berens

Leerink Partners

$40→$34

Buy

24.68%

Upside

Upgraded

11/20/25

Agios Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkAgios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink

Salveen Richter

Goldman Sachs

$40→$25

Hold

-8.32%

Downside

Reiterated

11/20/25

Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman SachsAgios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs

Luca Issi

RBC Capital

$57→$28

Hold

2.68%

Upside

Downgraded

11/19/25

Agios downgraded to Sector Perform from Outperform at RBC CapitalAgios downgraded to Sector Perform from Outperform at RBC Capital

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

10/30/25

Agios Pharma: Strong Market Performance and Promising Pipeline Justify Buy Rating

Greg Harrison

Scotiabank

$65

Buy

138.36%

Upside

Reiterated

08/05/25

Scotiabank Remains a Buy on Agios Pharma (AGIO)

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Agios Pharma (AGIO)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Viatris (NASDAQ: VTRS), Agios Pharma (NASDAQ: AGIO) and Phreesia (NYSE: PHR)

Alec Stranahan

Bank of America Securities

$32

Buy

17.35%

Upside

Reiterated

12/09/25

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)We reiterate Buy and $32 PO.

Tessa Romero

J.P. Morgan

―

Hold

―

Reiterated

12/08/25

Agios Pharma: Hold Rating Amid Regulatory Uncertainty and Gradual Market Launch

Emily Bodnar

H.C. Wainwright

$48

Buy

76.02%

Upside

Reiterated

12/08/25

Samantha Semenkow

Citi

$38

Buy

39.35%

Upside

Initiated

11/26/25

Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)Agios Pharmaceuticals initiated with a Buy at Citi (yesterday)

Andrew Berens

Leerink Partners

$40→$34

Buy

24.68%

Upside

Upgraded

11/20/25

Agios Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkAgios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink

Salveen Richter

Goldman Sachs

$40→$25

Hold

-8.32%

Downside

Reiterated

11/20/25

Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman SachsAgios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs

Luca Issi

RBC Capital

$57→$28

Hold

2.68%

Upside

Downgraded

11/19/25

Agios downgraded to Sector Perform from Outperform at RBC CapitalAgios downgraded to Sector Perform from Outperform at RBC Capital

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

10/30/25

Agios Pharma: Strong Market Performance and Promising Pipeline Justify Buy Rating

Greg Harrison

Scotiabank

$65

Buy

138.36%

Upside

Reiterated

08/05/25

Scotiabank Remains a Buy on Agios Pharma (AGIO)

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

05/13/25

Cantor Fitzgerald reiterates Overweight Rating on Agios Pharma (AGIO)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

1 Month

xxx

Success Rate

12/16 ratings generated profit

Average Return

+1.76%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +1.76% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+8.72%

upgraded a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.72% per trade.

1 Year

Andrew BerensLeerink Partners

Success Rate

9/14 ratings generated profit

Average Return

+24.78%

upgraded a buy rating 26 days ago

Copying Andrew Berens's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +24.78% per trade.

2 Years

xxx

Success Rate

13/14 ratings generated profit

Average Return

+56.97%

upgraded a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +56.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGIO Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AGIO has received 14 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. AGIO average Analyst price target in the past 3 months is 34.17.

Each month's total comprises the sum of three months' worth of ratings.

AGIO Financial Forecast

AGIO Earnings Forecast

Next quarter’s earnings estimate for AGIO is -$1.95 with a range of -$2.09 to -$1.80. The previous quarter’s EPS was -$1.78. AGIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AGIO has Performed in-line its overall industry.

AGIO Sales Forecast

Next quarter’s sales forecast for AGIO is $12.10M with a range of $9.28M to $13.44M. The previous quarter’s sales results were $12.88M. AGIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AGIO has Performed in-line its overall industry.

AGIO Stock Forecast FAQ

What is AGIO’s average 12-month price target, according to analysts?

Based on analyst ratings, Agios Pharma’s 12-month average price target is 34.17.

What is AGIO’s upside potential, based on the analysts’ average price target?

Agios Pharma has 25.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AGIO a Buy, Sell or Hold?

Agios Pharma has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Agios Pharma’s price target?

The average price target for Agios Pharma is 34.17. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $25.00. The average price target represents 25.30% Increase from the current price of $27.27.

What do analysts say about Agios Pharma?

Agios Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of AGIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Agios Pharma (AGIO) Stock Forecast & Price Target

AGIO Analyst Ratings

AGIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agios Pharma

AGIO Analyst Recommendation Trends

AGIO Financial Forecast

AGIO Earnings Forecast

AGIO Sales Forecast

AGIO Stock Forecast FAQ

Detailed List of Analyst Forecasts